Xeris 10-Q: Q3 Revenue $107.2M, Net Income $11.3M; Cash $131.1M
XERS has more than doubled off its 52-week low of $5.25 on elevated volume (4.8× avg).
Summary
Xeris' Q3 10-Q confirms the $107.2 million revenue and $11.3 million net income already reported, with $131.1 million of cash and the convertible debt fully retired, leaving only the $200 million term loan due 2029.
Key Events · Earnings and Guidance · XERS
-
Q3 Revenue Up 44% to $107.2M
Total revenue of $107.2 million versus $74.4 million a year ago, with Recorlev up 93.5% to $71.5 million and net income of $11.3 million, or $0.06 per diluted share.
-
Operating Cash Flow Jumps to $53.6M
Nine-month operating cash flow of $53.6 million versus $8.6 million in 2025; cash and equivalents rose to $131.1 million from $111.0 million at December 31, 2025.
-
Convertible Notes Retired, Term Loan Remains
The 2028 Convertible Notes were settled in July 2026 with 8.6 million shares and $23.1 million cash, producing a $30.8 million non-cash extinguishment loss; the $200.0 million Hayfin term loan matures March 5, 2029.
-
Recorlev Patent Trial Set for November 2028
Five ANDA filers challenge four Orange Book patents expiring March 2040; the consolidated case has a bench trial tentatively scheduled for November 2028, with FDA approval stayed until up to June 30, 2029.
Analysis · XERS · Life Sciences
The headline numbers were already out this morning, but the full 10-Q reveals the quality of the quarter: $53.6 million of operating cash flow in nine months versus $8.6 million a year ago, and $131.1 million of cash against a single $200 million term loan due March 2029 after the 2028 convertible notes were fully retired in July. The nine-month net loss of $17.6 million is entirely driven by the $30.8 million non-cash extinguishment charge on that convertible exchange, not operations. The offsetting risk is concentration: Recorlev is now the growth engine at $71.5 million for the quarter, and five ANDA filers are challenging its Orange Book patents, with trial not until November 2028.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XERS was trading at $12.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $5.25 to $13.74. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.